• Users Online: 229
  • Print this page
  • Email this page

Table of Contents
Year : 2020  |  Volume : 3  |  Issue : 3  |  Page : 638-640

Outcome of chronic lymphocytic leukemia with deletion 17p

1 Department of Medical Oncology, Dr. B.R.A. IRCH, All India Institute of Medical Sciences, New Delhi, India
2 Department of Medical Oncology, Lab Oncology Unit, Dr. B.R.A. IRCH, All India Institute of Medical Sciences, New Delhi, India

Date of Submission31-May-2020
Date of Decision14-Jun-2020
Date of Acceptance11-Aug-2020
Date of Web Publication19-Sep-2020

Correspondence Address:
Ajay Gogia
Department of Medical Oncology, Dr. B.R.A. IRCH, All India Institute of Medical Sciences, New Delhi
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/CRST.CRST_215_20

Get Permissions

How to cite this article:
Gogia A, Kumar L, Sharma A, Gupta R, Rani L. Outcome of chronic lymphocytic leukemia with deletion 17p. Cancer Res Stat Treat 2020;3:638-40

How to cite this URL:
Gogia A, Kumar L, Sharma A, Gupta R, Rani L. Outcome of chronic lymphocytic leukemia with deletion 17p. Cancer Res Stat Treat [serial online] 2020 [cited 2020 Oct 28];3:638-40. Available from: https://www.crstonline.com/text.asp?2020/3/3/638/295546

In chronic lymphocytic leukemia (CLL), deletion of the short arm of chromosome 17 (del17p) is a rare genomic aberration found in about 5%–9% of the untreated patients in the Western countries and in around 12% in India.[1],[2] The presence of this deletion is associated with an inadequate response to chemotherapy, thereby resulting in an unfavorable outcome.[3],[4] The data on the outcomes of Indian patients with CLL harboring del 17p are scarce. In this prospective study, we recruited all consecutive patients diagnosed with treatment naïve and relapsed/refractory (R/R) CLL, registered at the Department of Medical Oncology, of the All India Institute of Medical Sciences, New Delhi, between June 2013 and December 2018. The diagnosis of CLL and treatment response were assessed based on the guidelines from the International Workshop on CLL.[5] Fluorescence in situ hybridization was used for the diagnosis of del17p from the peripheral blood samples using the commercially available dual color Zytolight TP53/Cen17 probe as per the manufacturer's recommendations (Zytovision, GmbH, Germany). At least 200 interphase nuclei per patient were visualized using the Olympus fluorescence microscope (Japan). Those with a positive signal in ≥7.5% of the interphase nuclei were considered as harboring del17p.[2] The progression-free survival (PFS) was defined as the time from the date of initiation of treatment to relapse, disease progression, or death due to any cause.

A total of 220 patients were recruited in this study, of which 150 were newly diagnosed and 70 had R/R CLL. Of these, del17p was detected in a total of 36 patients, 18 (12%) with newly diagnosed, and 18 (25.5%) with R/R CLL. The baseline clinical and hematological parameters of the 36 patients are shown in [Table 1]. The median age of the cohort was 57 years (range, 35–80 years), and the female–to-male ratio was 1:5. Zeta-chain-associated protein kinase-70 was positive in 17 (58.6%, n = 29), CD 38 in 14 (45.1%, n = 31), and CD49d in 18 (66.6%, n = 27) patients; a total of 24 patients (13 with newly diagnosed and 17 with R/R CLL) did not harbor any mutations in the IGVH gene. The mutation status was documented only once during the course of treatment. Of the 18 patients with newly diagnosed CLL, 11 received treatment (4 with ibrutinib; 4 with bendamustine and rituximab [BR]; 2 with chlorambucil and prednisolone [CP]; and 1 with fludarabine, cyclophosphamide, and rituximab [FCR]), whereas 7 patients were kept under observation. The overall response rate (ORR) was 63.6% (7 out of 11 patients), and complete response (CR) was seen in 36.36% (4 out of 11) of the patients. Of 18 patients with R/R CLL, 15 received treatment (4 with ibrutinib; 4 with BR; 5 with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone/rituximab, cyclophosphamide, vincristine, prednisolone; and 2 with CP); the observed ORR was 40%, and the CR rate was 13%. The different regimens used in the management of CLL in our cohort are listed in [Table 2]. Eighteen patients died, 11 due to disease progression, 4 due to infections, and 3 due to other reasons. In addition, 8 patients developed Richter's syndrome and died. The median PFS of the cohort was 14 months (16 months for those with newly diagnosed CLL and 7 months for those with R/R disease) during a median follow-up period of 29 months. The estimated 5-year overall survival rate of the cohort was 40%.
Table 1: Clinico-hematological parameters of patients with chronic lymphocytic leukemia with 17p del (de novo and relapsed/refractory)

Click here to view
Table 2: Different treatment regimens used in the management of chronic lymphocytic leukemia with 17p deletion

Click here to view

Del17p is usually seen in about 50% of the R/R CLL cases.[1] It is associated with high-risk disease in patients who have indications and progress to require treatment.[6] The response to standard first-line chemo-immunotherapeutic agents is inadequate in patients with CLL harboring del17p.[3],[4] The ORR reported with standard-of-care first-line FCR was 70%, with a median PFS of 11 months.[6],[7] The results of alemtuzumab (either as monotherapy or with steroids), BR, and lenalidomide with rituximab have been disappointing.[8],[9]

In the present study, the incidence of del17p was 25.5% in the R/R cases, which is comparatively lower than that reported in the literature from the Western world. This may be due to a selection bias, as we had not routinely tested for del17p at the time of second or third relapse and beyond. The most commonly used chemo-immunotherapeutic agent in our study was BR. FCR was used only in one patient in our study because of its unfavorable toxicity profile in our population.[10] Currently, newer oral drugs such as the Bruton kinase inhibitors (ibrutinib and acalabrutinib); BCL2 inhibitors (venetoclax), either alone or in combination with obinutuzumab; and phosphatidylinositol 3-kinase inhibitors (duvelisib and idelalisib) have been shown to have better efficacy and safety profiles over chemotherapy.[11] In our study, ibrutinib could be used in only eight patients because of financial constraints. Generic brands of ibrutinib and other oral drugs were not available in India during the study period. Our study was limited by the unavailability of testing facilities for the other cytogenetic abnormalities. To the best of our knowledge, ours is the first Indian study reporting the outcomes of patients with CLL harboring del17p.

In conclusion, the incidence of R/R CLL in our cohort was 25.5%, and the outcome was dismal with chemo-immunotherapeutic agents. The generic brand of Bruton kinase inhibitors is currently available at a lower cost in India, which might improve the survival outcomes in our population.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

  References Top

Zenz T, Gribben JG, Hallek M, Döhner H, Keating MJ, Stilgenbauer S. Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood 2012;119:4101-7.  Back to cited text no. 1
Gogia A, Gupta R, Kumar L, Sharma A, Soni L. Chronic lymphocytic leukemia with deletion 17p: An Indian scenario. South Asian J Cancer 2019;8:40.  Back to cited text no. 2
[PUBMED]  [Full text]  
Badoux XC, Keating MJ, Wierda WG. What is the best frontline therapy for patients with CLL and 17p deletion? Curr Hematol Malig Rep 2011;6:36-46.  Back to cited text no. 3
Strati P, Keating MJ, O'Brien SM, Ferrajoli A, Burger J, Faderl S, et al. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica 2014;99:1350-5.  Back to cited text no. 4
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on chronic lymphocytic leukemia updating the national cancer institute-working group 1996 guidelines. Blood 2008;111:5446-56.  Back to cited text no. 5
Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, et al. Early results of a chemo-immunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-88.  Back to cited text no. 6
Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-74.  Back to cited text no. 7
Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616-23.  Back to cited text no. 8
Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J, et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 2011;118:3489-98.  Back to cited text no. 9
Gogia A, Sharma A, Raina V, Kumar L, Vishnubhatla S, Gupta R, et al. Assessment of 285 cases of chronic lymphocytic leukemia seen at single large tertiary center in Northern India. Leuk Lymphoma 2012;53:1961-5.  Back to cited text no. 10
Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification, and treatment. Am J Hematol 2019;94:1266-87.  Back to cited text no. 11


  [Table 1], [Table 2]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
Article Tables

 Article Access Statistics
    PDF Downloaded17    
    Comments [Add]    

Recommend this journal